Global Prospective, Observational Cohort of Adult Patients with Primary Sclerosing Cholangitis (WIND-PSC Study)

Description

Develop an appropriate real-world data comparator cohort to support the design, execution, and serve as an external control for interventional clinical trials in PSC.

Conditions

PSC

Study Overview

Study Details

Study overview

Develop an appropriate real-world data comparator cohort to support the design, execution, and serve as an external control for interventional clinical trials in PSC.

A Global Multi-Center Prospective Observational Cohort to Support Drug Development in Adult Patients with Primary Sclerosing Cholangitis (WIND-PSC)

Global Prospective, Observational Cohort of Adult Patients with Primary Sclerosing Cholangitis (WIND-PSC Study)

Condition
PSC
Intervention / Treatment

-

Contacts and Locations

Miami

Schiff Center for Liver Diseases / University of Miami, Miami, Florida, United States, 33136

Boston

Massachusetts General Hospital, Boston, Massachusetts, United States, 02114

Richmond

Virginia Commonwealth University, Richmond, Virginia, United States, 23298

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Adult patients between 18 and 75 years of age (inclusive) who can comprehend instructions, follow the study procedures and are willing to sign an Informed Consent Form (ICF).
  • 2. Confirmed clinical diagnosis of large duct PSC based on current AASLD Guidelines (Bowlus 2023).
  • 1. Clinically significant acute or chronic liver disease of an etiology other than PSC (with or without presence of features of AIH).
  • 2. Small-Duct PSC.
  • 3. Clinically diagnosed secondary or IgG4-related sclerosing cholangitis.
  • 4. Clinically diagnosed acute cholangitis and currently receiving treatment. Patients on chronic suppressive antibiotics will be allowed to enroll.
  • 5. UDCA dose \>28 mg/kg
  • 6. Evidence of current or historical decompensated cirrhosis based on the following clinical events:
  • * Ascites \> Grade 2 and requiring treatment
  • * Esophageal or gastric variceal bleeding requiring hospitalization
  • * Hepatic encephalopathy (as defined by a West Haven score ≥ 2)
  • * Spontaneous bacterial peritonitis defined as ascites absolute neutrophil count \>250/mm3 in the absence of an intra-abdominal source of infection
  • * AKI-HRS according to AASLD Guidelines (Flamm 2021)
  • 7. Prior liver transplantation
  • 8. MELD-Na Score \>15. For subjects on anticoagulation medication, baseline INR determination for MELD score calculation should take this use into account.
  • 9. Participants with current clinical or laboratory evidence of any severe, progressive, or uncontrolled disease, related or unrelated to PSC and which, in the opinion of the investigator, has an expected survival of less than 48 weeks.
  • 10. Participants who are impaired, incapacitated, or incapable of completing study- related assessments or giving informed consent.
  • 11. Prisoners or participants who are involuntarily incarcerated.
  • 12. Participants who are currently participating in an interventional clinical study.
  • 13. Absence of data in medical records to assess inclusion and exclusion criteria.

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

PSC Partners Seeking a Cure,

Cynthia Levy, MD, PRINCIPAL_INVESTIGATOR, University of Miami

Stephen Rossi, PharmD, PRINCIPAL_INVESTIGATOR, PSC Partners Seeking a Cure

Study Record Dates

2031-01